Cardiometabolic & kidneySecondary analysis
Impact of Canagliflozin on Heart Stress and Outcomes: Pooled Insights from CREDENCE and CANVAS
- Pooled secondary analysis of the CANVAS and CREDENCE randomised trials
- subgroup analysis by heart stress
- multivariable Cox models
Authors' conclusion
Age-adjusted NT-proBNP thresholds effectively predict cardio-kidney events in at-risk type 2 diabetes individuals without HF. Canagliflozin offers strong cardiovascular and kidney protection, with the greatest benefits in those with heart stress
Study context
- Population
- T2DM with cardio-renal disease and no known heart failure (HF) at baselineCANVAS + CREDENCE
- Participants
- 5,281 participants
- Comparison
- Canagliflozin effects by heart stress
- Primary endpoint
- Composite of:
- End-stage kidney disease
- Doubling of serum creatinine
- Kidney
- CV death
Primary result
As reported in the abstract
Canagliflozin effect in participants with heart stress
Canagliflozin vs No heart stressHazard ratio (95% CI)
primary composite, heart stress
0.72(0.62–0.84)
kidney composite, heart stress
0.65(0.53–0.79)
HF hospitalization, heart stress
0.68(0.54–0.85)
Further findings
Heart stress prevalence and prognosis · baseline and year 1
- Heart stress at baseline
- 45%
- Heart stress independently predicted increased risks for all outcomes; highest with persistent or rising NT-proBNP
- Rising NT-proBNP by year 1 associated with higher risk
Original publication
Impact of Canagliflozin on Heart Stress and Outcomes: Pooled Insights from CREDENCE and CANVAS. Eur J Heart Fail. Published 21 July 2025. doi:10.1002/ejhf.3786
Summarised from the published abstract; every number is checked against it